Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats. 2014

Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, P.R. China.

Elevation of intracellular cyclic adenosine monophosphate (cAMP) levels facilitates recovery following spinal injury by suppressing secondary pathology and promoting axonal regeneration. However, this treatment strategy is limited by lack of effective and tolerable clinical agents. The present study examined the effects of meglumine cyclic adenylate (MCA) on neurological recovery, cAMP concentration, adenylate cyclase 3 (AC3) activity and phosphodiesterase 4D (PDE4D) activity during early stage acute spinal cord injury (SCI) in rats. A total of 48 Sprague‑Dawley rats were randomly assigned to groups A, B or C, each consisting of 16 animals. SCI was induced by Allen's method using a 7 g x 3 cm extradural weight‑drop impact on spinal cord segment T11. A total of 30 min following SCI, group A received a single 30 mg/kg‑bw i.p. dose of methylprednisolone, group B received 2 mg/kg‑bw i.p. MCA daily for seven days and group C were administered an equal volume of normal saline. Seven days following SCI, the spinal cord samples from eight rats per group were obtained to measure the cAMP concentration, and the activities of AC3 and PDE4D. The remaining eight rats per group were used for behavioral assessments using the inclined plane stability test and Gale scale for up to six weeks post‑SCI. The drug‑treated groups A and B had higher cAMP concentrations and AC3 activities but lower PDE4D activities at the lesion sites, as well as superior behavioral scores post‑SCI compared with the vehicle‑treated group C (P<0.05). Furthermore, cAMP was higher in group B than in group A (P<0.05). It was concluded that MCA may serve as an effective SCI treatment by activating AC3 and suppressing PDE4D.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008536 Meglumine 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium. Methylglucamine
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors

Related Publications

Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
August 2023, Spinal cord,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
January 2024, Journal of physiological investigation,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
July 2017, Chinese journal of integrative medicine,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
April 1998, Journal of neurotrauma,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
February 2004, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
January 2007, Basic & clinical pharmacology & toxicology,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
January 1999, Acta neurochirurgica,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
October 2000, Journal of neurosurgery,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
December 2008, Experimental neurology,
Jingwu Liao, and Jingming Xie, and Daqiang Lin, and Ning Lu, and Limin Guo, and Weiqiang Li, and Bo Pu, and Yang Yang, and Zhenlong Yang, and Ying Zhang, and Yueming Song
September 1988, Journal of neurosurgery,
Copied contents to your clipboard!